258 related articles for article (PubMed ID: 30779811)
1. Identification of HIV gp41-specific antibodies that mediate killing of infected cells.
Williams KL; Stumpf M; Naiman NE; Ding S; Garrett M; Gobillot T; Vézina D; Dusenbury K; Ramadoss NS; Basom R; Kim PS; Finzi A; Overbaugh J
PLoS Pathog; 2019 Feb; 15(2):e1007572. PubMed ID: 30779811
[TBL] [Abstract][Full Text] [Related]
2. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects.
Dupuy FP; Kant S; Barbé A; Routy JP; Bruneau J; Lebouché B; Tremblay C; Pazgier M; Finzi A; Bernard NF
mBio; 2019 Dec; 10(6):. PubMed ID: 31848282
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal Antibody 2C6 Targets a Cross-Clade Conformational Epitope in gp41 with Highly Active Antibody-Dependent Cell Cytotoxicity.
Sojar H; Baron S; Sullivan JT; Garrett M; van Haaren MM; Hoffman J; Overbaugh J; Doranz BJ; Hicar MD
J Virol; 2019 Sep; 93(17):. PubMed ID: 31217246
[TBL] [Abstract][Full Text] [Related]
5. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities.
Alsmadi O; Tilley SA
J Virol; 1998 Jan; 72(1):286-93. PubMed ID: 9420226
[TBL] [Abstract][Full Text] [Related]
6. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
Zwick MB; Labrijn AF; Wang M; Spenlehauer C; Saphire EO; Binley JM; Moore JP; Stiegler G; Katinger H; Burton DR; Parren PW
J Virol; 2001 Nov; 75(22):10892-905. PubMed ID: 11602729
[TBL] [Abstract][Full Text] [Related]
7. Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells.
Richard J; Nguyen DN; Tolbert WD; Gasser R; Ding S; Vézina D; Yu Gong S; Prévost J; Gendron-Lepage G; Medjahed H; Gottumukkala S; Finzi A; Pazgier M
mBio; 2021 Oct; 12(5):e0140521. PubMed ID: 34579568
[TBL] [Abstract][Full Text] [Related]
8. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.
Wibmer CK; Gorman J; Ozorowski G; Bhiman JN; Sheward DJ; Elliott DH; Rouelle J; Smira A; Joyce MG; Ndabambi N; Druz A; Asokan M; Burton DR; Connors M; Abdool Karim SS; Mascola JR; Robinson JE; Ward AB; Williamson C; Kwong PD; Morris L; Moore PL
PLoS Pathog; 2017 Jan; 13(1):e1006074. PubMed ID: 28076415
[TBL] [Abstract][Full Text] [Related]
9. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.
Nelson JD; Kinkead H; Brunel FM; Leaman D; Jensen R; Louis JM; Maruyama T; Bewley CA; Bowdish K; Clore GM; Dawson PE; Frederickson S; Mage RG; Richman DD; Burton DR; Zwick MB
Virology; 2008 Jul; 377(1):170-83. PubMed ID: 18499210
[TBL] [Abstract][Full Text] [Related]
10. Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.
Gohain N; Tolbert WD; Acharya P; Yu L; Liu T; Zhao P; Orlandi C; Visciano ML; Kamin-Lewis R; Sajadi MM; Martin L; Robinson JE; Kwong PD; DeVico AL; Ray K; Lewis GK; Pazgier M
J Virol; 2015 Sep; 89(17):8840-54. PubMed ID: 26085162
[TBL] [Abstract][Full Text] [Related]
11. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
Duchemin M; Khamassi M; Xu L; Tudor D; Bomsel M
Front Immunol; 2018; 9():244. PubMed ID: 29651286
[TBL] [Abstract][Full Text] [Related]
12. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection.
Acharya P; Tolbert WD; Gohain N; Wu X; Yu L; Liu T; Huang W; Huang CC; Kwon YD; Louder RK; Luongo TS; McLellan JS; Pancera M; Yang Y; Zhang B; Flinko R; Foulke JS; Sajadi MM; Kamin-Lewis R; Robinson JE; Martin L; Kwong PD; Guan Y; DeVico AL; Lewis GK; Pazgier M
J Virol; 2014 Nov; 88(21):12895-906. PubMed ID: 25165110
[TBL] [Abstract][Full Text] [Related]
13. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.
Guan Y; Pazgier M; Sajadi MM; Kamin-Lewis R; Al-Darmarki S; Flinko R; Lovo E; Wu X; Robinson JE; Seaman MS; Fouts TR; Gallo RC; DeVico AL; Lewis GK
Proc Natl Acad Sci U S A; 2013 Jan; 110(1):E69-78. PubMed ID: 23237851
[TBL] [Abstract][Full Text] [Related]
14. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
[TBL] [Abstract][Full Text] [Related]
15. Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.
Trott M; Weiβ S; Antoni S; Koch J; von Briesen H; Hust M; Dietrich U
PLoS One; 2014; 9(5):e97478. PubMed ID: 24828352
[TBL] [Abstract][Full Text] [Related]
16. Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses.
Pollara J; Bonsignori M; Moody MA; Pazgier M; Haynes BF; Ferrari G
Curr HIV Res; 2013 Jul; 11(5):378-87. PubMed ID: 24191939
[TBL] [Abstract][Full Text] [Related]
17. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.
Finnegan CM; Berg W; Lewis GK; DeVico AL
J Virol; 2002 Dec; 76(23):12123-34. PubMed ID: 12414953
[TBL] [Abstract][Full Text] [Related]
18. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
Nyambi PN; Mbah HA; Burda S; Williams C; Gorny MK; Nádas A; Zolla-Pazner S
J Virol; 2000 Aug; 74(15):7096-107. PubMed ID: 10888650
[TBL] [Abstract][Full Text] [Related]
19. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.
Shen X; Parks RJ; Montefiori DC; Kirchherr JL; Keele BF; Decker JM; Blattner WA; Gao F; Weinhold KJ; Hicks CB; Greenberg ML; Hahn BH; Shaw GM; Haynes BF; Tomaras GD
J Virol; 2009 Apr; 83(8):3617-25. PubMed ID: 19193787
[TBL] [Abstract][Full Text] [Related]
20. Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity.
Pietzsch J; Scheid JF; Mouquet H; Seaman MS; Broder CC; Nussenzweig MC
J Virol; 2010 May; 84(10):5032-42. PubMed ID: 20219932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
